1. Home
  2. NCRA vs LYRA Comparison

NCRA vs LYRA Comparison

Compare NCRA & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.28

Market Cap

5.6M

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.33

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
LYRA
Founded
2002
2005
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.6M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
NCRA
LYRA
Price
$0.28
$1.33
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
114.5K
64.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,534,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.08
52 Week High
$2.40
$37.50

Technical Indicators

Market Signals
Indicator
NCRA
LYRA
Relative Strength Index (RSI) 33.41 40.29
Support Level N/A $1.21
Resistance Level $0.45 $1.52
Average True Range (ATR) 0.07 0.15
MACD 0.01 0.06
Stochastic Oscillator 12.00 72.12

Price Performance

Historical Comparison
NCRA
LYRA

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: